Immunopathogenic Treatment Options for Psoriasis Patients Under a Restrictive Reimbursement Environment
, , y
22 jul 2021
Acerca de este artículo
Publicado en línea: 22 jul 2021
Páginas: 158 - 166
Recibido: 11 jun 2020
Aceptado: 01 mar 2021
DOI: https://doi.org/10.2478/prolas-2021-0025
Palabras clave
© 2020 Ilona Hartmane et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Hartmane, Ilona
Clinical Centre of Skin and Sexually Transmitted DiseasesLatvia
Department of Dermatology, Rīga Stradiņš UniversityLatvia
Ivdra, Iveta
Clinical Centre of Skin and Sexually Transmitted DiseasesLatvia
Department of Dermatology, Rīga Stradiņš UniversityLatvia
Mikažāns, Ingmārs
Clinical Centre of Skin and Sexually Transmitted DiseasesLatvia
Department of Dermatology, Rīga Stradiņš UniversityLatvia
Bondare-Ansberga, Vanda
Clinical Centre of Skin and Sexually Transmitted DiseasesLatvia